Journal
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY
Volume 34, Issue 6, Pages 632-641Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/03639040701834078
Keywords
oridonin; 2-hydroxypropyl-beta-cyclodextrin; inclusion complex; characterization; pharmacokinetics; tissue distribution
Categories
Ask authors/readers for more resources
Oridonin, a diterpenoid, is a sparingly soluble compound and its aqueous solubility can't meet the requirement of clinical intravenous administration. This study was, accordingly, to prepare an inclusion complex of oridonin and 2-hydroxypropyl-beta-cyclodextrin (HP-beta-CD) by lyophilization to improve its apparent solubility. The solubility enhancement of oridonin was evaluated by phase solubility method, and the phase solubility curve displayed a typical AL-type, indicating the formation of 1:1 inclusion complex. The formation of inclusion complex was confirmed by DSC, XRD, FTIR, and NMR, and thereby two possible inclusion modes were inferred. In vivo studies demonstrated that HP-beta-CD had no significant effect on the plasma pharmacokinetic behaviors of oridonin following i.v. administration to rats, but the inclusion complex tended to decrease the distribution of oridonin in heart, spleen, and kidney and increase that in lung in mice, compared to that of free drug.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available